Elan Drug Technologies Corporate Profile

Article

Elan Drug Technologies, the world?s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products.

Elan Drug Technologies, the world’s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products. With over 40 years experience in the drug delivery business, we have successfully brought 36 drugs to market for clients in over 100 markets. We have successful collaborations with the majority of the world’s leading pharma companies with client annual in-market sales of over $3 billion.

Drug optimization, development and manufacture
Elan has a unique platform of technologies to offer our clients - from oral controlled release, delayed release, pulsatile release delivery systems to technology solutions for poorly water soluble compounds. We have a complete range of capabilities from formulation development through to commercial scale manufacture in modern facilities. Our technologies are supported by a robust patent estate of over 1,900 patents / patent applications. Elan has developed unique capabilities to from early stage development right through to full scale final dosage form manufacture.

INVITATION TO MEET WITH US
Join us at CPhI Worldwide Annual meeting from October 5-7 in Paris where we will at booth location 5D63. To organise a meeting e-mail us at edtqueries@elan.com or check out our website to see the range of services we offer.
www.elandrugtechnologies.com

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Drug Digest: Focusing on Solid Dosage Trends and Demand
Behind the Headlines, episode 7
Related Content